



Ascendant Capital Markets LLC serves as Financial Advisor on \$10,220,000 Private Placement for Outlook Therapeutics, Inc., Increases Total Amount to \$30,040,000 Over Four Transactions

JUPITER, Florida – November 18, 2021 -- Ascendant Capital Markets LLC (“Ascendant”) announced today the closing of a \$10,220,000 private placement for Outlook Therapeutics, Inc. (Nasdaq: OTLK) of Iselin, New Jersey.

Ascendant served as Financial Advisor on the financing, which increased the total amount to \$30,040,000 over four transactions.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENATM (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHS 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

About Ascendant Capital Markets LLC

Ascendant Capital Markets, LLC, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendant has led or participated in over \$1 billion in financing transactions, and the members of Ascendant’s Investment Banking Team have completed over 300 M&A transactions.

Ascendant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 561.427.1727 or bwilhite@ascendant.com.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

ASCENDANT CAPITAL MARKETS, LLC

110 Front Street, Suite 300, Jupiter, Florida 33477

561.427.7788 | www.ascendant.com

Member FINRA & SIPC